Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06CWZ
|
|||
| Drug Name |
CAR-CLD18 T cell
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Adenocarcinoma [ICD-11: 2D40] | Clinical trial | [1] | |
| Pancreatic cancer [ICD-11: 2C10; ICD-9: 157] | Clinical trial | [1] | ||
| Company |
Kang YU
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Claudin-18 (CLDN18) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Tight junction | ||||
| Leukocyte transendothelial migration | ||||
| Hepatitis C | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Reactome | Tight junction interactions | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.